ArticleStem cell research & therapy2025
Therapeutic application of EUS-guided intraportal autologous bone marrow transplantation for decompensated liver cirrhosis.
Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
BACKGROUND AND
aimsTo compare the efficacy and safety of different treatment regimens for decompensated liver cirrhosis (DLC), focusing on the novel method of endoscopic ultrasound (EUS)-guided intraportal autologous bone marrow transplantation (ABMT).
methodsIn this study, 65 DLC patients were assigned to one of three groups: EUS-POV ABMT (n = 22), PEV ABMT (n = 20), or conventional treatment (n = 23), and followed for 12 months. An exploratory analysis investigated the impact of graft quality (CD34 + cell proportion) on outcomes in the ABMT cohort.
resultsThe EUS-POV group and PEV group that received ABMT showed different degrees of improvement in routine blood tests, transaminases, albumin levels, Child-Pugh scores, and coagulation function compared with the conventional treatment group, the clinical symptoms were relieved, with no apparent adverse reactions. The EUS-POV group was more effective than the PEV group in improving albumin levels and activated partial thromboplastin time (P < 0.05); notably, histopathological improvement was observed in the EUS-POV group. An exploratory subgroup analysis based on CD34 + cell proportion (dichotomized by an ROC-derived cutoff) did not reveal a significant difference in the trajectory of liver function improvement between high and low CD34 groups. Importantly, linear mixed-model analysis revealed that the transplantation route, not the CD34 + cell proportion, was the primary factor associated with therapeutic efficacy (Interaction effect: P = 0.936).
conclusionsEUS-guided intraportal ABMT is a safe and highly effective treatment for DLC, demonstrating clear advantages over peripheral infusion due to superior targeting and sustained clinical benefits. The success of ABMT appears to be influenced more critically by the cell delivery route than by the progenitor cell content of the graft.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.